HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

STLN

The Oncology Institute, Inc. (NASDAQ)

Healthcare — Medical Care Facilities

Starling Oncology, Inc., an oncology company, provides various oncology services in the United States. It operates through three segments: Specialty pharmacy, Patient Services, and Clinical Trials & Other. The company offers physician services, in-house infusion, in-house specialty pharmacy, clinical trials, radiation therapy, and outpatient blood product transfusion services, as well as educational seminars, support groups, counseling services, and 24/7 patient assistance and support services. It also manages clinical trials and palliative care programs; operates combined community clinics and infusion suites; and operates a specialty pharmacy that includes both in-office and mail-order dispensing for complementary oral and self-injectable medications taken by patients concurrent with their in-office cancer therapies. It serves adult and senior cancer patients. The company was formerly known as The Oncology Institute, Inc. and changed its name to Starling Oncology, Inc. in August 2026. Starling Oncology, Inc. was founded in 2007 and is headquartered in Cerritos, California.

Strong Buy 1.2 / 5 5 analysts
$6.56
+$0.29 (+4.71%)
Target: $9.00 (37.3%)

Price History

52-Week Range
Sign in to add STLN to a watchlist or set price alerts.

Fundamentals

Market Cap$625.76M
P/E Ratio (TTM)-
Forward P/E-
EPS (TTM)$-0.29
Dividend Yield-
Profit Margin-6.18%
Revenue Growth34.60%
ROE-
Debt/Equity-
Recommendation Strong Buy 1.2
Analyst Target$9.00
Analysts5
Indexes NASDAQ

Technical Indicators

RSI (14)61.7
Beta0.42
SMA 20$5.32
SMA 40$5.40
52-Week High$7.05
52-Week Low$2.32
50-Day Avg$5.26
200-Day Avg$3.90
Avg Volume$1.98M
Volume$1.11M

Performance Analysis

BULLISH

STLN shows predominantly bullish signals based on its fundamentals and technicals.

+ Showing strength at 90% of its 52-week range.
+ RSI at 61.7 shows positive momentum.
+ Price is above both the 50-day and 200-day moving averages — strong uptrend.
+ Strong revenue growth of 34.6% year-over-year.
- Operating at a loss with -6.2% margin.
+ Wall Street consensus is "Strong Buy" from 5 analysts.
+ Average analyst target of $9.00 implies 37.3% upside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Aug 11, 2026 16:55 UTC

Back to Screener Export Report